All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Researchers from Institute of Medicinal Biotechnology have published details on the discovery of novel nonsteroidal farnesoid X receptor (FXR) agonists as potential therapeutic agents for the treatment of nonalcoholic steatohepatitis (NASH).
